← Leaderboards
David J Cole
Medical University Of South Carolina
$5,413,185
Attributed
$5,413,185
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $972.9K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$5,413,185 · 7
By mechanism
R01$4,231,565 · 2
P01$972,858 · 2
R29$207,212 · 1
M01$1,550 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoDesignTumor AntigensBaseProgramsCellsGenesTumorLeadResponseResearch PersonnelApoptoticLaboratory MouseAffectLeukocyte Activation /TransformationPhenotypeCytotoxic T LymphocyteMolecularDendritic CellsIn VitroMalignant NeoplasmsInnovationMelanomaT Cell Receptor
Grant awards (24)
Clinical Trials using TCR Transduced T Cells for Adoptive Immunotherapy$693,336
P01 · FY2012 · CA · contact PI
TCR Transduced CD8+ T Cells for Adoptive Immunotherapy$279,522
P01 · FY2012 · CA · contact PI
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER$270,405
R01 · FY2011 · CA · contact PI
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER$278,768
R01 · FY2010 · CA · contact PI
Targeting Early Activated T cells for Adoptive Therapy$259,295
R01 · FY2010 · CA · contact PI
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER$278,768
R01 · FY2009 · CA · contact PI
Targeting Early Activated T cells for Adoptive Therapy$259,295
R01 · FY2009 · CA · contact PI
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER$278,768
R01 · FY2008 · CA · contact PI
Altering Post Vaccination T Cell Contraction$249,183
R01 · FY2008 · CA · contact PI
CLINICAL TRIAL: ACTIVE IMMUNOTHERAPY AFTER RESECTION OF HEPATIC METASTASES OF CO$1,550
M01 · FY2008 · RR · contact PI
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER$287,508
R01 · FY2007 · CA · contact PI
Altering Post Vaccination T Cell Contraction$249,183
R01 · FY2007 · CA · contact PI
Altering Post Vaccination T Cell Contraction$126,418
R01 · FY2007 · CA · contact PI
Altering Post Vaccination T Cell Contraction$256,624
R01 · FY2006 · CA · contact PI
Altering Post Vaccination T Cell Contraction$125,799
R01 · FY2006 · CA · contact PI
Altering Post Vaccination T Cell Contraction$262,800
R01 · FY2005 · CA
Altering Post Vaccination T Cell Contraction$113,565
R01 · FY2005 · CA
Altering Post Vaccination T Cell Contraction$262,800
R01 · FY2004 · CA
IN VIVO EFFECTOR CELL RESPONSE TO PEPTIDE VACCINATION$225,225
R01 · FY2003 · CA
IN VIVO EFFECTOR CELL RESPONSE TO PEPTIDE VACCINATION$225,225
R01 · FY2002 · CA
IN VIVO EFFECTOR CELL RESPONSE TO PEPTIDE VACCINATION$221,936
R01 · FY2001 · CA
T CELL RECOGNITION OF TUMOR ANTIGEN$105,568
R29 · FY2001 · CA
T CELL RECOGNITION OF TUMOR ANTIGEN$101,644
R29 · FY2000 · CA
CEA VACCINIA VIRUS W/ POST VACCINATION CEA PEPTIDE BOOST$0
M01 · FY2000 · RR